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Current therapies for Alzheimer’s disease (AD) are symptomatic and do
not target the underlying Aβ pathology and other important hallmarks
including neuronal loss. PPARγ-coactivator-1α (PGC-1α) is a cofactor for
transcription factors including the peroxisome proliferator-activated
receptor-γ (PPARγ), and it is involved in the regulation of metabolic
genes, oxidative phosphorylation, and mitochondrial biogenesis.
We previously reported that PGC-1α also regulates the transcription
of β-APP cleaving enzyme (BACE1), the main enzyme involved in Aβ
generation, and its expression is decreased in AD patients. We
aimed to explore the potential therapeutic effect of PGC-1α by gen-
erating a lentiviral vector to express human PGC-1α and target it by
stereotaxic delivery to hippocampus and cortex of APP23 transgenic
mice at the preclinical stage of the disease. Four months after injec-
tion, APP23 mice treated with hPGC-1α showed improved spatial and
recognition memory concomitant with a significant reduction in Aβ
deposition, associated with a decrease in BACE1 expression. hPGC-1α
overexpression attenuated the levels of proinflammatory cytokines and
microglial activation. This effect was accompanied by a marked preser-
vation of pyramidal neurons in the CA3 area and increased expression
of neurotrophic factors. The neuroprotective effects were secondary to
a reduction in Aβ pathology and neuroinflammation, becausewild-type
mice receiving the same treatment were unaffected. These results sug-
gest that the selective induction of PGC-1α gene in specific areas of the
brain is effective in targeting AD-related neurodegeneration and holds
potential as therapeutic intervention for this disease.
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Alzheimer’s disease (AD) is the most prevalent form of de-mentia in the elderly and affects more than 40 million people
worldwide. The global cost of dementia is estimated at more than
800 billion USD, without effective treatment that can at least halt,
cure, and prevent the disease (World Alzheimer’s report 2015, ref.
1). Current drug therapies for AD are merely symptomatic and do
not target the underlying cause of the disease. New strategies include
disease-modifying treatments, which aim to reduce the production of
amyloid-β (Aβ) peptides and plaques or the modified protein tau
and tangles. These particular therapies are expected to block the
progression of the disease and prevent neuronal loss, but are likely
also to have serious side effects (2, 3).
We have recently explored the potential neuroprotective effects of
the PPARγ-coactivator 1α (PGC-1α), a transcriptional coactivator
for the peroxisome proliferator-activated receptor-γ (PPARγ) and
for other transcription factors (4). PGC-1α is abundantly expressed
in high-energy demanding tissues such as adipose tissue, liver, skel-
etal muscle, heart, kidney, and brain (5, 6) where it is involved in the
regulation of glucose and lipid metabolism, oxidative phosphoryla-
tion, and mitochondrial biogenesis (4, 5).
PGC-1α has been implicated in various neurodegenerative diseases
(6) and its expression is reduced in the brain of AD patients (7, 8).
Interestingly, exogenous human PGC-1α expression in neuroblas-
toma cells and in primary neurons from the Tg2576 mouse model of
AD decreased Aβ generation and increased nonamyloidogenic
sAPPα levels (7, 8). Additionally, we showed that PGC-1α me-
diates this effect by reducing β-APP cleaving enzyme (BACE1)
gene transcription via a PPARγ-dependent mechanism (7).
Conversely, crossing Tg2576 with mice deficient in PGC-1α or
silencing PGC-1α using siRNA transfection in neuronal cells, led
to increased Aβ levels (7–9). Pharmacological stimulation of
PGC-1α synthesis with nicotinamide riboside, the precursor of
NAD+, resulted in reduced Aβ levels and attenuated cognitive
deterioration in Tg2576 mice (9). Furthermore, treatment with
resveratrol, another PGC-1α activator, increased the activity of
the Aβ-degrading enzyme neprilysin and reduced amyloid plaques
(10). Nevertheless, these drugs may promote these beneficial ef-
fects by acting on molecules other than PGC-1α, and an additional
independent approach to investigate these specific functions of
PGC-1α in AD was therefore considered relevant. We hypothe-
sized that gene therapy with PGC-1α delivered in the brain could
be neuroprotective because of its effect on the transcription of
genes involved in Aβ generation, energy and glucose metabolism,
and oxidative stress.
The aim of this study was to generate a lentiviral vector expressing
human PGC-1α and target it in defined brain regions of APP23
transgenic mice by stereotaxic delivery, allowing us to evaluate the
specific effects of this transcriptional regulator and define its po-
tential for gene therapy for AD. Our results show that PGC-1α
prevents neuronal loss by increasing the transcription of growth
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factors and by decreasing Aβ-mediated neuroinflammation in those
animals, consolidating the potential of PGC-1α gene delivery as
treatment for AD.
Results
Effective Transduction of PGC1α Using RVG-B2c Lentiviral Vectors
Confers Neurotropism and High Expression in the Brain. Lentiviral
vectors (LV) that efficiently transduce neurons were generated,
compared by various combinations of gene promoters and viral
envelope glycoproteins. We first tested vesicular stomatitis viral
glycoprotein (VSVG) and rabies virus glycoprotein B2c (RVG).
Pseudotyping lentiviral vectors with the RVG envelope glyco-
protein confers both neurotropism and, more importantly, the
ability of retrograde transport along neuronal axons (11). Addi-
tionally, we compared lentiviral vectors carrying the ubiquitous
human CMV major immediate-early enhancer/promoter or the
neuronal-specific human synapsin I (SYN) gene promoter. We
generated combinations of VSVG-CMV, VSVG-SYN, RVG-
CMV, and RVG-SYN vectors that carried the enhanced GFP
(eGFP) gene and injected them unilaterally in the brain of wild-type
mice (SI Text and Fig. S1 A–L). RVG-CMV resulted in higher
expression, transduced cells both proximal and distal to the site of
injection and preferentially transduced pyramidal neurons in the
cortex and the CA1 area of the hippocampus (HIP) (Fig. S1 G–L).
CMV promoter was selected because it resulted in higher expres-
sion compared with the SYN promoter (Fig. S1 E–M). The neu-
rotropism of the vector was confirmed by costaining for eGFP and
NeuN (Fig. 1 A–D), and by showing little or no localization of the
transgene with astrocytes or microglia by costaining of eGFP with
Iba1 and GFAP (Fig. 1 E–H). Therefore, the RVG-CMV-eGFP
LV and RVG-CMV- hPGC-1α LV (further referred as LV-eGFP
and LV-hPGC-1α) were generated as the vectors of choice (Fig. 1I).
The efficiency of the lentiviral vectors LV-eGFP and LV-
hPGC-1α injected in the cortex and HIP of wild-type and APP23
mice was measured 4 mo after injection (p.i.). The expression of
hPGC-1α protein in the brain of injected mice was evaluated by
IHC using an antibody against the V5 tag, at the N terminus of
the hPGC-1α construct (Fig. 1J). Moreover, hPGC-1α mRNA
expression was confirmed by quantitative RT-PCR (qRT-PCR)
analysis in the HIP, parietal cortex (Pt Ctx), and frontal cortex
(Ft Ctx) of the injected APP23 mice (Fig. 1K).
hPGC-1α Gene Delivery Improves Spatial and Recognition Memory in
APP23 Mice. We next determined the therapeutic effects of long-
term overexpression of hPGC-1α in the cortex and HIP of wild-
type and APP23 mice, delivering it at the age of 8 mo and lasting
for 4.5 mo (Fig. 2A). At 8 mo, female APP23 mice show the first
rare amyloid deposits, representing the preclinical stage of the
disease (12–14). To assess any adverse effects, we monitored
several parameters after surgery, including body weight, mobility,
and anxiety (Supporting Information and Fig. S2 A–C).
To define whether chronic expression of LV-hPGC-1α in the
cortex and HIP of APP23 and wild-type mice affected their
memory, behavioral tests were carried out 4 mo p.i. Spatial
memory was evaluated by object location task (OLT), based on
the spontaneous tendency of rodents to spend more time ex-
ploring a relocated object (Fig. 2B and Fig. S2D). The APP23
mice (at 12 mo of age) that received the control vector displayed
spatial memory deficits and were not able to discriminate be-
tween the displaced and the nondisplaced object (Fig. 2B).
Conversely, APP23 animals injected with LV-hPGC-1α showed
no deficits in spatial memory and performed as well as the two
groups of wild-type mice, all preferring the displaced object (Fig.
2B). Following OLT, the mice were subjected to the novel object
recognition test (NOR), which measures their ability to explore
longer a novel object over a familiar one (Fig. 2C and Fig. S2E).
The results of the NOR revealed that the APP23/LV-hPGC-1α
mice were able to discriminate and explored for a longer time the
Fig. 1. RVG-CMV lentiviral vector confers high transgene expression in
neurons of hPGC-1α lentiviral-injected mice. (A–D) Representative images of
the CA1 area of HIP for eGFP (green), NeuN (red), and GFAP (blue) from RVG-
CMV-eGFP–injected wild-type mice showing clear colocalization of NeuN
and eGFP and little or no colocalization of eGFP with GFAP. (E–H) Repre-
sentative images of the CA1 area of HIP show low colocalization of microglia
(Iba1-red) or astrocytes (GFAP-blue) with the transgene (eGFP-green) in RVG-
CMV-eGFP–injected APP23 mouse brains. (I) Schematic of the genome plas-
mids used to generate the LV vectors. The upper construct represents the
pRRL-sincppt-CMV-eGFP-WPRE and the lower one the pRRL-sincppt-CMV-
hPGC-1α-WPRE lentiviral genome plasmids. (J) Anti-V5 immunohistochem-
istry in a LV-hPGC-1α–injected mouse 4.5 mo p.i. confirmed expression of the
transgene in cortex and HIP. Tiled images were obtained at 10× magnifi-
cation and generated by Image-Pro Plus 6 software. Inset shows a magnifi-
cation of CA3 area. (K) Quantitative mRNA analysis for hPGC-1α showed
increased expression in HIP (n = 6), parietal cortex (Pt Ctx; n = 7) and frontal
cortex (Ft Ctx; n = 5) of LV-hPGC-1α–injected APP23 compared with the
APP23/LV-eGFP mice 4 mo p.i. *P < 0.05, **P < 0.01, two-tailed Student’s t
test. (Scale bars: 50 μm.)
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novel object, whereas the APP23/LV-eGFP mice showed profound
deficits (Fig. 2C). It is worth noting that the expression of hPGC-1α
in the brain did not improve the performance of wild-type mice (Fig.
2C). These combined results demonstrate that lentiviral-mediated
hPGC-1α expression prevented memory deficits in APP23 mice.
hPGC-1α Chronic Overexpression Reduces BACE1, Aβ Levels, and
Plaque Load in APP23 Mice. To quantify Αβ load by IHC, we used
a monoclonal Aβ-specific antibody that does not cross-react with
full-length APP or carboxy-terminus domains (CTFs) (15). Histo-
pathological examination revealed significantly lower Αβ burden in
cortex (19.1% reduction) and HIP (30% reduction) in APP23/LV-
hPGC-1α mice compared with animals injected with the con-
trol vector (Fig. 3 A–C). Plaque burden was quantified after brain
sections were stained with AmyloGlo, instead of the standard
Thioflavin-S dye, because this interfered with eGFP detection. We
observed that the area covered by amyloid plaques was decreased in
the APP23/LV-hPGC-1α mice, both in the cortex and HIP com-
pared with the APP23/LV-eGFP mice (43% and 51% decrease,
respectively) (Fig. 3 D–F). Western blot analysis of brain homog-
enates confirmed the immunohistological results, showing reduced
Aβ levels in the APP23/LV-hPGC-1α mice compared with APP23
mice treated with control vector (Fig. 3 G and H and Fig. S3 A and
B). In addition, decreased ELISA values for Aβ40 and Aβ42 sub-
types in the same samples corroborated these results (Fig. 3I),
without changes in their ratio (Fig. S3C). Our previous in vitro
studies demonstrated that increased PGC-1α expression reduces
Bace1 transcription (7). In line with those in vitro results, the brain
levels of β-CTF and sAPPβ, the main products of BACE1, were
remarkably reduced in APP23 mice that received LV-hPGC-1α
compared with APP23 injected with LV-eGFP (Fig. 3 J and L and
Fig. S3 A and B), without changes in the expression of the precursor
protein APP (Fig. 3K and Fig. S3 A and B). In complete agreement,
the chronic expression of hPGC-1α in the brain of APP23 mice
lowered BACE1 protein levels compared with control mice (Fig.
3M). Interestingly, an inverse correlation between hPGC-1α and
Bace1mRNA levels indicated lower Bace1mRNA expression to be
associated with higher PGC-1α levels (Fig. 3N; Pearson’s r =−0.7255,
P < 0.05). Although no major changes were detected in sAPPα and
αCTFs, the products of α-secretase cleavage, the ratio sAPPα/sAPPβ
was found strongly increased, indicating a shifting in the balance
toward α-secretase byLV-hPGC-1α delivery (Fig. S3 D and E).
Furthermore, overexpression of hPGC-1α increased Adam17
mRNA levels but did not significantly affect Adam10 mRNA
(Fig. S3 K and L). No significant alterations were observed in the
Aβ clearance or degradation mechanisms (Fig. S3 F–J andM–O).
Together, our combined data demonstrate that LV-hPGC-1α
CNS transduction resulted in higher levels of human PGC-1α,
triggering a robust reduction of Aβ production and plaque for-
mation, however, not by affecting Aβ clearance or degradation.
hPGC-1α Attenuates Neuroinflammation in APP23 Mice. The APP23
mouse model of brain amyloidopathy exhibits a strong neuro-
inflammatory component (12–14). We quantified the density of
microglia and astrocytes in areas surrounding amyloid plaques of
Fig. 2. Cortical and hippocampal expression of hPGC-1α prevents memory
decline in APP23 mice. (A) Schematic representation of the experimental
procedure. Mice were injected at 8 mo of age, and behavioral tests were
carried out 1 mo and 4 mo p.i., when tissues were harvested. (B) APP23/LV-
hPGC-1α mice 4 mo after surgery had intact spatial memory assessed by object
location task (OLT), whereas the APP23/LV-eGFP–injected mice showed mem-
ory deficits. The shaded columns show the displaced object (D) and the non-
shaded the nondisplaced object (ND). (C) NOR testing session showing that the
APP23/LV-hPGC-1α mice had recognition memory values similar to the wild-
type levels, whereas the APP23/LV-eGFP were unable to discriminate between
the novel (labeled N, shaded columns) and the familiar object (labeled F) (n =
8–10). Two-tailed Student’s t test, *P < 0.05, **P < 0.01; ***P < 0.001.
Fig. 3. Cortical and hippocampal sustained expression
of hPGC-1α decreases amyloid plaque load in APP23
mice. (A and B) Representative images of anti-Aβ
(MOAB-2) immunostained sections of APP23 injected
with LV-eGFP and LV-hPGC-1α, respectively. (C) Quan-
tification of percentage of Aβ burden from MOAB-2
staining revealed a significant decrease in Aβ load in LV-
hPGC-1α/APP23 mice compared with LV-eGFP/APP23
(n = 9). (D and E) Representative sections stained with
AmyloGlo and quantification of percentage of plaque
burden (F) revealed a significant decrease in LV-hPGC-
1α/APP23 mice (n = 9, seven sections per mouse). Tiled
digital images of sections were obtained at 10× mag-
nification using Image-Pro Plus 6 software. Represen-
tative Western blots for Aβ (G) and their quantification
(H) and ELISA for Aβ40 and Aβ42 (I) in frontal cortex
homogenates demonstrated decreased Aβ levels by
hPGC-1α overexpression (n = 5). (J and K) Quantifica-
tion fromG showed reductions in β-CTFs levels, whereas
full-length APP expression was unchanged in APP23/LV-
PGC-1α (n = 5). (L) Representative Western blots for
sAPPα and sAPPβ in cortices showing decrease in sAPPβ
(n = 5 for each group). (M) RepresentativeWestern blot
and quantification showed reduced BACE1 expres-
sion in the frontal cortex of LV-hPGC-1α/APP23 (n = 5),
(N) Correlation analysis of BACE1 mRNA and hPGC-
1α mRNA showing a statistically significant inverse
correlation (Pearson’s r = −0.7255, P = 0.0417). *P <
0.05, two-tailed Student’s t test.
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similar size (Fig. 4 A–L). Microglial activation was detected by IHC
for Iba-1 and found attenuated in APP23 injected with LV-hPGC-
1α compared with animals injected with control vector (Fig. 4 B,D–F,
and H–J). We did not observe major changes in astrocytosis sur-
rounding the plaques, detected by GFAP staining (Fig. 4 C, D, G,
H, K, and L), although total GFAP expression was reduced in
hippocampal homogenates of APP23/LV-hPGC-1α mice (Fig. 4M).
Importantly, the expression of the main proinflammatory cytokines
TNF-α and IL-1β was significantly reduced in the APP23/LV-
hPGC-1α mice compared with the APP23/LV-eGFP mice (Fig. 4 N
and O), whereas no significant changes were observed for IL-6,
IL-10, and MCP-1 (Fig. 4 P–R). In summary, hPGC-1α affects the
activation of microglia, reducing their proinflammatory profile.
hPGC-1α Prevents Neuronal Loss in the Hippocampus of APP23 Mice.
APP23 mice suffer neuronal loss in specified hippocampal areas at
age 12 mo (16) and was confirmed by immunohistochemical
analysis with NeuN in brains of APP23/LV-eGFP mice, showing a
30% reduction in neuronal number in the CA3, compared with
wild-type/LV-eGFP mice (Fig. 5 A, C, E, G, I). Remarkably, in
APP23 mice treated with LV-hPGC-1α, we observed a marked
preservation of pyramidal neurons in the CA3 (Fig. 5 D, H, I),
consistent with the absence of memory impairment described
above. We found no significant changes in neuronal density in the
dentate gyrus and subiculum in LV-hPGC-1α–injected mice (Fig.
5J and Fig. S4 A–E), suggesting that the neuroprotective effect was
not linked to increased neurogenesis. In addition, PGC-1α gene
delivery did not alter neuronal count in the brains of wild-type
mice, indicating that the positive effect on neurons was associated
with reduced amyloid load and pathology (Fig. 5 A, B, E, G, I).
This conclusion was further supported by data showing increased
mRNA expression of the neuroprotective factor (Fig. 5K) and the
levels of the postsynaptic protein PSD-95 only in APP23/LV-
hPGC-1α and not in wild-type mice (Fig. 5M and Fig. S4F).
Interestingly, the expression of Ngf was found increased in both
wild-type and APP23 mice overexpressing hPGC-1α (Fig. 5L).
Discussion
The present study shows that gene delivery of hPGC-1α in the
brain of transgenic APP23 mice reduced amyloid deposition,
improved memory, and prevented neuronal loss. Importantly, we
describe a potential treatment that can preserve neuronal viability
and improve memory in AD, corroborating other neuroprotective
approaches such as gene therapy with growth factors. This ap-
proach was recently highlighted in AD patients treated with NGF
gene delivery, which revealed increased axonal sprouting, cell
hypertrophy, and activation of functional markers (17).
The observed PGC-1α–mediated positive effects, however, do
not seem to involve alterations in neuronal proliferation, because
the preservation of dentate gyrus integrity, an area directly in-
volved in neurogenesis, remained unchanged by LV-hPGC-1α.
Most interestingly, increased expression of neurotrophic factors
Fig. 4. LV-hPGC-1α gene delivery in cortex and HIP of APP23 mice reduces neuroinflammation. (A–H) Representative cortical images from confocal imaging of triple
staining for AmyloGlo (green), Iba1 (red), and GFAP (magenta) in LV-eGFP (A–D) and LV-hPGC-1α–injected APP23mice (E–H); n= 5. (Scale bars: 125 μm.) Quantification
of mean gray area (I) and percentage of coverage by microglial cells (J) showed amarked reduction of microglial activation in the APP23 mice LV-hPGC-1α (n = 5, four
sections per mouse). GFAP-positive astrocytes surrounding the plaques were quantified as mean gray area (K) or percentage of coverage (L) (n = 5, four sections
per mouse). (M) Representative Western blot in total hippocampal homogenates and quantification of GFAP (n = 5). (N–R) ELISAs for cytokines TNF-α (N), IL-1β
(O), IL-6 (P), IL-10 (Q), and MCP-1 (R) in the frontal cortices and hippocampi (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed Student’s t test.
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NGF and BDNF was evident following LV-hPGC-1α gene ther-
apy and both exert neuroprotective properties in AD (18, 19). In
line with our findings was the report showing that exercise-
induced BDNF expression was mediated by PGC-1α regulation
of Fndc5 gene expression (20). Moreover, PPARγ and PPARα,
the main transcription factors regulated by PGC-1α, induced the
transcription of BDNF in cultured neurons and glial cells (21, 22).
Combined, these data are fully consistent with a mechanism for
the neuroprotective effects of hPGC-1α in APP23 mice mediated,
at least partially, by increased transcription of specific growth
factors (Fig. S5K). Consistent with our results, previous work
demonstrated that PGC-1α knockout mice develop neurological
abnormalities and show prominent neurodegeneration (23, 24).
In addition, our data indicate that the beneficial effects on
memory and neurodegeneration are a consequence of the re-
duction in Aβ generation and the associated inflammatory re-
sponse, because memory, BDNF levels, PSD95 expression, and
neuronal numbers were not affected in wild-type mice that re-
ceived the same LV-hPGC-1α treatment. Therefore, the thera-
peutic effect of PGC-1α required a proinflammatory state to be
effective, in this case evidently caused by hAPP overexpression
and Aβ production in the APP23 mice (Fig. S5K). Furthermore,
because we found that hPGC-1α was mostly expressed in neurons, we
presume that the antiinflammatory reaction observed by hPGC-1α
delivery in the brain is secondary to the decrease on Aβ levels pro-
duced by neurons, because Aβ is able to induce a proinflammatory
reaction in the brain (25). Our results do not support a noticeable
involvement of enhanced mitochondrial function (Fig. S5) or the
autophagy/lysosomal pathway in the neuroprotective effects of
PGC-1α in APP23, as suggested in other neurological disease
models, such as Huntington’s disease (26).
A recent study of a bigenic model obtained crossing the Tg19959
with PGC-1α transgenic mice reported reductions in the levels of
Aβ40 by ELISA, whereas increased Congo red staining for ag-
gregated Aβ. The results of this publication were obtained from a
transgenic mouse overexpressing elevated levels of PGC-1α under
a promoter not specific for a particular cell type and, consequently,
the results do not necessarily have to coincide with our model, in
which the gene is expressed for only 4 mo in certain brain areas
(27). Indeed, sustained high overexpression of PGC-1α produced
toxic effects in muscles and heart, caused or accompanied by ex-
tensive mitochondrial proliferation and by myopathy (28, 29). Ex-
tremely high levels of PGC-1α achieved with adenoviral vectors
also resulted in deleterious effects in dopaminergic neurons, in
susbtantia nigra (30, 31) as opposed to the striatum, where fourfold
higher levels were not toxic, in mouse models of Huntington’s and
Parkinson’s diseases (32, 33). The different outcomes in different
studies must relate to the fact that dopaminergic neurons are more
susceptible to degeneration from oxidative damage than other
neuronal subtypes and suggest that selective delivery in specific
brain regions is necessary to achieve beneficial effects. The lentiviral
vector for delivery of hPGC-1α in our study was well tolerated, did
not trigger adverse effects, and allowed sustained expression of the
transgene for months. Successful proof-of-principle studies of gene
therapy using similarly pseudotyped lentiviral vectors have been
demonstrated in animal models of ALS (34, 35), spinal muscular
atrophy (36), and spinal nerve injury (37). In addition, we have
developed and tested a similar vector for dopamine replacement
therapy in late stage Parkinson’s disease patients in a phase I/II
clinical trial, showing long-term expression and improved motor
behavior in treated patients (38). We believe, therefore, that future
innovations in gene therapy provide hope and clinical potential also
in Alzheimer’s dementia. Although this method of delivery is at this
time invasive and, therefore, has some translational limitations, our
data provide a proof of concept for future drug discovery programs
aimed to induce the PGC-1α gene to target neurodegeneration.
Materials and Methods
Animals. Eight-month-old female APP23 mice (Novartis) and wild-type lit-
termates (C57BL/6) were used (12). The experiments were designed and
approved in compliance with the UK Home Office.
Lentiviral Vectors and Injections. Recombinant nonreplicative HIV-1–based LVs
were produced based on methods described (39) (SI Materials and Methods).
Immunohistochemistry and Immunofluorescence. Antibodies were incubated
overnight at 4 °C (anti-Αβ MOAB-2 1:1,000, anti-V5 1:500, and anti-NeuN,
1:500) and subsequent developing steps were performed as described (14)
(SI Materials and Methods). For immunofluorescent stainings, sections were
incubated with AmyloGlo (Biosensis) and primary antibodies against eGFP
(Abcam), Iba1 (Wako), GFAP (Invitrogen), and NeuN (Millipore) at 1:500 dilution
Fig. 5. Attenuation of neuronal loss in the CA3 area
of APP23 mice by hPGC-1α gene delivery. (A–D) Rep-
resentative pictures of NeuN staining in hippocampi
of wild-type/LV-eGFP (A), wild-type/LV-hPGC-1α (B),
APP23/LV-eGFP (C), and APP23/LV-hPGC-1α mice (D).
(E–H) Higher magnification images of A–D illustrat-
ing the striking reduction in neuronal loss in the CA3
area in APP23 mice that received LV-hPGC-1α.
(I) Quantification of neuronal numbers in the CA3
showing the neuroprotective effect of LV-hPGC1α
injection in APP23 mice (n = 3–5). Two-way ANOVA
test [Interaction F(1,13) = 9.275, P = 0.0094, Treatment
F(1,13) = 2.544, P = 0.134, Genotype F(1,13) = 34.27, P <
0.0001]. (J) Quantification of neuronal density in the
dentate gyrus (DG). (K) Bdnf mRNA detected by qRT-
PCR was significantly increased in HIP of APP23/LV-
hPGC-1α injected mice (n = 5). Two-way ANOVA
test [Interaction F(1,16) = 0.299, P < 0.05, Treatment
F(1,16) = 0.4178, P < 0.05, Genotype F(1,19) = 0.0407, P =
0.439]. (L) Ngf mRNA levels were significantly in-
creased in both wild types and APP23 injected with
LV-hPGC-1α. Two-way ANOVA test [Interaction F(1,18) =
0.0057, P = 0.092, Treatment F(1,18) = 0.628, P <
0.01, Genotype F(1,18) = 0.0197, P = 0.581], *P <
0.05, n = 5–6. (M ) Representative Western blot and
quantification for PSD-95 (n = 4), one-way ANOVA
***P < 0.001. (Scale bars: A–D, 0.250 mm; E–H,
0.1 mm.)
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and detected with secondary antibodies (AlexaFluor dyes; Invitrogen). Images
were captured by using a Leica SP5 Confocal microscope.
Protein Analysis. Western blot analysis was carried out as described (14) by
using antibodies against Aβ (clone 6E10) and sAPPβ (Covance), BACE1 (Cell
Signaling), PSD-95, IDE and LC3 (Abcam), COX-4 (from Kambiz Alavian, Im-
perial College London, London, UK), hPGC-1α and neprilysin (Santa Cruz) used
at a 1:1,000 dilution, R1(57) (from P. Mehta, New York State Institute for Basic
Research in Developmental Disabilities, Staten Island, NY) at a 1:2,000 di-
lution and 140 (from Jochen Walter, University Bonn, Bonn, Germany)
against CT-of APP and APOE (Santa Cruz) at a 1:500 dilution, V5 (Invitrogen)
at a 1:5,000, and LRP-1 (from Claus Pietrzik, University Mainz, Mainz, Germany)
and β-actin (Abcam) at a 1:10,000 dilution. The intensity of the bands was
quantified by densitometry using ImageJ software, and sample loading was
normalized to β-actin. The levels of human Αβ40 and Aβ42 were determined
by using a High Sensitivity Human Amyloid β40 and β42 ELISA kit (Millipore).
For the mouse cytokines, we used kits from Preprotech.
RNA Extraction and qRT-PCR. Tissues were lysed and homogenized in TRIzol re-
agent (Ambion), and total RNAwas isolated by using the RNeasymini kit (Qiagen).
First-strand cDNA was generated by using Taqman reverse transcription reagents
(Applied Biosystems) for Taqman Probes or QuantiTect Reverse Transcription kit
(Qiagen) for custom-made primers (SI Materials and Methods). qPCR was per-
formed by using TaqMan Universal PCRMaster Mix or Quantifast SYBR green in a
7900HT real-time PCR system (Applied Biosystems). mRNA quantities were nor-
malized to Gapdh after determination by the comparative Ct method.
Statistical Analysis. The data were analyzedwith GraphPad Prism version 6 and
SPSS version 20 (IBM) by using two-tailed Student’s t test or Mann–Whitney
test, two-way ANOVA followed by Bonferroni post hoc analysis and correla-
tion analysis. Power analysis was performed by using GPower 3.0. Columns
represent means ± SEM. Differences were considered significant for P < 0.5.
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Three weeks after injection (p.i.), we assessed the transduction
efficiency of the virus in areas proximal and distal to the injection
site in wild-type mice. Pseudotyping of the HIV-1–based lentiviral
vectors with VSVG was not found to be transported to distant
areas (Fig. S1 A–D). In addition, VSVG injections in the hippo-
campal formation preferentially transduced cells in the dentate
gyrus (DG) (Fig. S1 B and D). RVG-CMV vector’s higher ex-
pression and transduction efficiency together with its ability to
preferentially transduce pyramidal neurons (Fig. S1 E–M) was
more relevant for our purpose, because the APP23 mice express
hAPP in pyramidal neurons of cortical layers III-V and CA1-3
area in the HIP (12).
The gene delivery did not affect body weight, which was moni-
tored monthly [F(1,37) = 0.753, P = 0.391, n = 9–11; Fig. S2A]. The
performance of the mice in the open field evaluated at 1 and 4 mo
p.i. showed no effect of the treatment or of the genotype on ve-
locity or total distance moved (Fig. S2 B and C). Furthermore,
thigmotaxis (proximity to walls), reflecting anxiety, was also eval-
uated in the open field and was observed not to be significantly
affected (Fig. S2 B and C).
SI hPGC-1α Effect on Mitochondrial Markers in the Brains of
APP23 Mice
PGC-1α is the master regulator of mitochondrial biogenesis and
regulates the level and activity of numerous mitochondrial pro-
teins and enzymes that are essentially involved in major meta-
bolic and respiratory pathways (3, 5). We observed a significant
increase in the transcript levels of pyruvate dehydrogenase kinase-1
(Pdk1) in the parietal cortex of hPGC-1α–treated mice and in-
creased levels of other mitochondrial markers, including COX4,
sirtuin-1, and transcription factor A mitochondrial (Tfam), in the
brains of APP23/LV-hPGC-1α–injected mice compared with
control APP23/LV-eGFP mice (Fig. S5 A–J). Other mitochondrial
markers were unaltered by the LV-mediated hPGC-1α vector
injection. These results suggest that the beneficial effects of the
intracerebral hPGC-1α gene delivery do not appear to be directly
linked to major changes in mitochondrial function or biogenesis.
SI Materials and Methods
Animals.APP23mice express the hAPP cDNAcarrying the Swedish
mutation under the control of the neuronal-specific Thy1.2 pro-
moter and are characterized by amyloid deposition, plaque for-
mation, neuroinflammation, neuronal loss, and memory deficits
(12, 13). All of the animals were kept in individually ventilated
cages in a 12/12-h light/dark cycle with controlled temperature and
humidity and food and water ad libitum.
Lentiviral Vectors. The hPGC-1α complete coding sequences with
GenBank accession no. AF186379 was kindly provided by A. Kralli
(The Scripps Research Institute, La Jolla, California) and the HIV-1
packaging plasmids and pRR-sincppt-CMV-eGFP-WPRE were
kindly provided by James Uney (University of Bristol, Bristol, UK).
hPGC-1α was subcloned on the lentiviral transfer genome by re-
moving the eGFP cDNA (Fig. 1I). All vectors carry the woodchuck
hepatitis virus posttranscriptional regulatory element (WPRE).
Titration of LV Vectors. Biological titer of LV vectors carrying the
eGFP reporter gene was determined by flow cytometry as
described (39). The copy numbers of the viral preparations
were determined by using the Lenti-X qRT-PCR Titration kit
(Clontech) using a Lenti-X RNA known copy number sample to
generate a standard curve according to the manufacturer’s in-
structions. The biological titer of LV vectors containing hPGC-1α
was extrapolated after calculating the titration ratio of the LV-
eGFP (ratio = biological titer/qRT-PCR copies) and by presuming
that the two viruses have the same titration ratio, the biological
titer was calculated from the formula biological titer = titration
ratio/qRT-PCR copies.
Stereotaxic Surgeries. Animals were anesthetized (isoflurane 5%,
1 L/min O2) and positioned on a stereotactic frame (World Pre-
cision Instruments). Injections were performed bilaterally in the
frontal cortex and HIP by using a 33-gauge blunt needle attached
to a 5-mL Hamilton syringe (Hamilton Medical) at 0.2 μL/min
(isoflurane 2%, 0.5 L/min O2 for maintenance of anesthesia). The
frontal cortex and the HIP were injected with 2.5 μL and 1.5 μL of
viral preparation, respectively (titer of 1 × 109 TU/mL). Stereotactic
coordinates were calculated from bregma [cortex: anterior-posterior
(AP) +2.2 mm, medial-lateral (ML) ±1.8 mm, dorso-ventral (DV)
−3 mm to −0.5 mm, five deposits 0.5 mm apart, 0.5 μL/deposit;
HIP: anterior-posterior (AP) −2 mm, medio-lateral (ML) ±1.2 mm,
dorso-ventral (DV) −1.5 mm to −1.1 mm, three deposits 0.2 mm
apart, 0.5 μL per deposit].
Open Field.Mice were allowed to freely explore a 45 × 45 cm arena
for 5 min, and thigmotaxis, velocity, and total distance moved were
assessed by using Ethovision XT version 9 software (Noldus).
OLT. Hippocampal-dependent spatial memory of the mice was
tested by using the OLT. This task can assess learning impairment
that is attributed mainly to dysfunctional dorsal and CA1 area of
the HIP (40).
NOR Test.Recognition memory of the mice was tested by using the
NOR test. Previous studies have shown that parahippocampal
areas of the temporal lobe are involved and the hippocampal
formation by using a long delay (24 h) between training and testing
(41).Mice received 2 d of habituation in a 45 × 45 cm square arena,
and on the third day, they were allowed to explore two identical
objects made from large Lego bricks for 10 min (training trial)
(Fig. S2E). They were returned to their home cage, and 24 h later,
a different shape and color object replaced one of the objects and
the mice were returned to the arena for 10 min (testing trial). The
total time the animal spent exploring each object (characterized by
active sniffing or chewing) was recorded by using EthoVision XT
software (Noldus). The time spent on each object was then cal-
culated as a percentage of total object exploration.
Tissue Processing. Mice were deeply anesthetized with pentobar-
bitone and then transcardially perfused with 30 mL of ice-cold
PBS. The brains were rapidly removed, and the right hemisphere
was fixed in 4% (wt/vol) paraformaldehyde in PBS (0.1M, pH 7.4)
for 48 h, cryoprotected in 20% (wt/vol) sucrose in PBS (0.1 M, pH
7.4), and then sectioned at 35 μm by using a vibratome (Leica
VT100S). The left hemispheres were dissected, snap frozen, and
stored at −80 °C until used for biochemical analyses.
Immunohistochemistry and Immunofluorescence. Sections were treated
for 20 min with 0.6% H2O2 in TBS, permeabilized in TBS-Triton
X-100 0.25% (TBS-Tx) for 30 min, and blocked for 1 h with
10% (vol/vol) FBS in TBS-Tx 0.1%. For Αβ staining, an addi-
tional step of antigen retrieval with 98% (vol/vol) formic acid
was performed before permeabilization. Tiled digital images of
sections were obtained at 10× magnification, using a Nikon
Eclipse 50i microscope with QImaging Micropublisher 3.3 RTV
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digital camera, using Image-Pro Plus 6 software (Media Cyber-
netics). For fluorescent images, tiled digital images of sections were
obtained at 10× magnification, using a Nikon Eclipse 80i micro-
scope with QImaging Qi-Cam digital camera also using Image-Pro
Plus 6 software (Media Cybernetics).
Image Analyses. For assessing amyloid and plaque burden, the
percentage of the area covered by Aβ or AmyloGlo staining was
calculated by using the NIH ImageJ software (seven sections per
animal, n = 9). To obtain measures of Aβ-associated microgliosis
and astrocytosis, 50 μm2 and 100-μm2 diameter circles, respec-
tively, were centered over plaques to define plaque domains and
then superimposed on images of Iba1-stained microglia and
GFAP-stained astrocytes. Fluorescent intensities were calculated
within each plaque domain in at least three plaques per section
and expressed as mean gray area (corresponding to mean pixel
intensity, four sections per animal, n = 5). Additionally, the extent
of plaque-associated microgliosis and astrocytosis was analyzed by
thresholding the images and measuring the percentage of area
occupied by Iba1- and GFAP-positive cell bodies and processes
within individual plaque domains, serving as an indication of the
number of cells bodies around the plaques (42). For neuronal cells
quantifications, we measured the number of positive cells in three
random squares 150 × 150 μm for subiculum, and 100 × 100 μm
for CA3 and the area occupied by the dentage gyrus.
Western Blotting. Mouse brain samples were homogenized in
radioimmunoprecipitation assay buffer (1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS, 150 mM NaCl, and 50 mM
Tris·HCl, pH 7.2) supplemented with protease and phosphatase
inhibitors (Roche).
Determination of Soluble-APP (sAPPα and sAPPβ) and APP CTFs. To
determine soluble APP and αCTFs in brain homogenates, 50 μg
were pulled down overnight at 4 °C by using Sepharose Protein A
(Zymed) and 140, a polyclonal antibody recognizing the CT-domain
of APP (from JochenWalter, University of Bonn, Bonn, Germany)
to immunoprecipitate full-length APP. Samples were then spun
down and pellets were then loaded in NuPage 4–12% Tris-glycine
gels and transferred onto nitrocellulose membranes and incubated
with R1-57 antibody for CTFs determination. Supernatants were
run in 10% (wt/vol) SDS gels and incubated with 6E10 antibody at
1/1,000 (a monoclonal antibody recognizing amino acids 1–17 of
human Aβ; Covance) for sAPPα and with an antibody against
sAPPβ from Covance.
Primers Used in qRT-PCR. Bace1 (QT00493948) Quantitect
Primer assays from Qiagen; Adam10 (Mm00545742_m1),
Adam17 (Mm00456428_m1), Bdnf (Mm432069_m1), Foxo1
(Mm00490672_m1),Gapdh(Mm99999915_g1), Ide (Mm00473077_m1),
Mme/Nep (Mm00485028_m1), Nrf1 (00447996_m1), PPARGC1A/
PGC-1A (Hs01016719_m1), Pdk1 (Mm00554306_m1), Sirt1
(Mm01168521_m1), Tfam (Mm00447485_m1), Taqman gene ex-
pression assays from Applied Biosystems; Aco2 (for: 5′-TG-
ATGCAAACCCTGAGACC-3′, rev: 5′-GAGCCTCCAACTTGA-
ACTTCT-3′), ApoE (for: 5′-CTGACAGGATGCCTAGCCG-3′,
rev: 5′-CGCAGGTAATCCCAGAAGC-3′), Cox6 (for: 5′-TCA-
TATTGCTGGCGCATTC-3′, rev: 5′-CCTTCCTCATCTCTTC-
GAAATC-3′), CS (for: 5′-CCAATCTGCACCCTATGTCTC-3′,
rev: 5′-GTCCATGCAGTCCTCATAGATG-3′), Gapdh (for:
5′-ACCACAGTCCATGCCATCAC-3′, rev: 5′-TCCACCAC-
CCTGTTGCTGTA-3′), Ngf (for: 5′-CCAGTGAAATTAG-
GCTCCCTG-3′, rev: 5′-CCTTGGCAAAACCTTTATTGGG-3′)
and Pfk (for: 5′-AAGTCTGCCATCACCTGACC-3′, rev: 5′-TC-
CCACAAGACATACACATGG-3′), custom-made from Sigma-
Aldrich UK.
Statistics. All data were checked for normal distribution by using
the Kolmogorov–Smirnov normality test, the Levene median test
to ensure that variances are equal, and the Mauchly test of sphe-
ricity before performing the appropriate statistical analysis.
Fig. S1. Expression analysis of viral envelope glycoproteins and promoters. (A–L) Different glycoproteins and promoters were trialed with lentiviral vectors
and their biodistribution was examined 3 wk poststereotaxic delivery in the frontal cortex and HIP of wild-type mice. Expression was confirmed in several brain
areas both proximal and distal to the injection sites (n = 3, 16–20 sections). (Scale bars: 250 μm.) (M) HEK293T cells were transfected with the transfer genome
plasmid for CMV-eGFP, CMV-hPGC-1α, and SYN-hPGC-1α, respectively. Representative Western blots of cell lysates for the V5 tag of hPGC-1α, hPGC-1α, and
β-actin as loading control.
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Fig. S2. (A) Monthly weight monitoring showed no effect between the two viral vectors on body weight (two-way repeated-measures ANOVA F(1,37) = 0.753,
P = 0.391, n = 9–11). (B) Open field performance 1 mo after surgery showing no difference between the four groups of mice (two-way ANOVA followed by
Bonferroni post hoc test; Distance moved: Genotype F(1,37) = 0.0066, P = 0.9358, Treatment F(1,37) = 0.071, P = 0.7917; Velocity: Genotype F(1,37) = 0.0071, P =
0.9332, Treatment F(1,37) = 0.072, P = 0.7916; Thigmotaxis: Genotype F(1,37) = 2.902, P = 0.0968, Treatment F(1,37) = 0.2056, P = 0.6529; n = 9–11). (C) Open field
performance 4 mo after surgery did not differ between the 4 groups. (two-way ANOVA followed by Bonferroni post hoc test; Distance moved: Genotype F(1,37) =
0.107, P = 0.652, Treatment F(1,37) = 0.01, P = 0.921; Velocity: Genotype F(1,37) = 0.444, P = 0.510, Treatment F(1,37) = 0.207, P = 0.652; Thigmotaxis: Genotype F(1,37) =
0.744, P = 0.395, Treatment F(1,37) = 0.855, P = 0.361; n = 9–11). (D) OLT training session showing no preference for object A or B. (E) Mice explored the two objects
equally during the NOR training session.
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Fig. S3. Effects of hPGC-1α overexpression on APP processing and Aβ clearance and degradation. (A and B) Representative Western blots for Aβ, β-CTFs, and
APP from hippocampi (A) and their quantification (B) demonstrated that hPGC-1α overexpression decreased total Aβ and β-CTFs, whereas full-length APP
expression was unchanged APP23/LV-PGC-1α (n = 5 for each group). (C) Ratio of Aβ40/Aβ42 from the ELISAs in frontal cortex homogenates showed no dif-
ferences between groups. (D) Ratio analysis of sAPPα/sAPPβ revealed a shift toward the nonamyloidogenic pathway in LV-hPGC-1α/APP23 mice (n = 5).
(E) Representative Western blot in frontal cortex homogenates with the R1(57) antibody that recognizes the C terminus of APP showed no differences in α-CTFs
between the two groups. (F–I) Chronic overexpression of LV-hPGC-1α did not alter the expression of APOE and its receptor LRP-1 (F and G) or the Aβ-degrading
enzymes neprilysin and IDE (H and I) (n = 5, two-tailed Student’s t test). APOE, apolipoprotein E; IDE, insulin-degrading enzyme; LRP-1, low-density lipoprotein
receptor-related protein 1; NEP, neprilysin. (J) No changes were detected in autophagy by Western blotting for LC3 between LV-eGFP– and LV-PGC-1α–injected
APP23 mice. (K) Increased Adam17 mRNA levels in the cortex of LV/hPGC-1α APP23 mice compared with APP23/LV-eGFP. Hippocampus (HIP; n = 6), parietal
cortex (Pt Ctx; n = 7), and frontal cortex (Ft Ctx; n = 5). (L–O) The mRNA levels of Adam10, ApoE, Nep, and Ide remained largely unaffected by the hPGC-1α LV
injection (n = 6 for HIP, n = 7 for Pt Ctx, and n = 5 for Ft Ctx, two-tailed Student’s t test, *P < 0.05, **P < 0.01).
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Fig. S4. Neuronal cell density in subiculum of animals injected with LV-hPGC-1α or LV-eGFP. (A–D) Representative images of the subiculum where no changes
were detected between LV-eGFP– (A, wild-type; C, APP23) and LV-hPGC-1α–injected mice (B, wild-type; D, APP23). (Scale bars: 0.1 mm.) (n = 3 for wild-type and
n = 5 for APP23, six sections per mouse). (E) Quantification of NeuN+ cells in the subiculum of APP23 mice injected with LV-eGFP or LV-hPGC-1α showed no
significant differences in the neuronal numbers (n = 5, six sections per mouse, two-tailed Student’s t test). (F) Western blot for PSD-95 in wild-type mice showed
no changes between wt/LV-eGFP and wt/LV-hPGC-1α (two-tailed Student’s t test, n = 4).
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Fig. S5. Quantification of the expression of mitochondrial markers in brains of APP23/LV-hPGC-1α mice compared with APP23/LV-eGFP. (A) Representative
Western blot of COX-4 (two animals from each group shown here) and its quantification (n = 5, two-tailed Student’s t test). (B–F) The mRNA expression of the
mitochondrial markers Aco2 (B), CS (C), Pfk (E), and Cox6 (F) appears to be unaltered. There was a significant increase of Pdk1 (D) in the parietal cortex, which
was the area that had the highest expression of hPGC-1α (**P < 0.01, two-tailed Student’s t test). (G–J) qRT-PCR for Sirt1 (G), Tfam (H), Nrf1 (I), and Foxo1
(J) showed that LV-hPGC-1α did not change their expression. Hippocampus (HIP; n = 6), parietal cortex (Pt Ctx; n = 7), and frontal cortex (Ft Ctx; n = 5). Aco2,
aconitase 2; Cox-4, cytochrome c oxidase subunit IV; Cox-6, cytochrome c oxidase subunit VI; CS, citrate synthase; Foxo1, forkhead box O1; Nrf1, nuclear re-
spiratory factor 1; Pdk1, pyruvate dehydrogenase kinase; Pfk, phosphofructokinase; Sirt1, sirtuin 1; Tfam, transcription factor A mitochondrial. Data are shown
as mean ± SEM, and all samples were run in duplicates. (K) Schematic model showing the mechanistic effects of PGC-1α gene therapy in AD, by affecting BACE1
transcription-leading to reduced Aβ generation and neuroinflammation and increasing the expression of neurotrophic growth factors.
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